Extract
The lung clearance index (LCI) is a measure of ventilation distribution derived from multiple breath washout (MBW). It is a promising measure for monitoring early lung disease in cystic fibrosis (CF) [1–4] and is increasingly being used as a surrogate efficacy endpoint in CF clinical trials [5, 6]. LCI is reliable and more sensitive than forced expiratory volume in 1 s (FEV1) in detecting lung disease in infants, children and adults with CF [7–9], tracks early disease progression and symptoms [3], and predicts the onset of pulmonary exacerbations [10]. LCI has been shown to be elevated in infants and younger children with respiratory infection and correlates with airway inflammation, measured using a range of biomarkers in bronchoalveolar lavage [11–13]. However, there are few data on how LCI relates to markers of infection and inflammation in children >6 years and adults.
Abstract
LCI is a sensitive marker of infection and inflammation in clinically stable children and adults with cystic fibrosishttp://ow.ly/vumZ30hzHL0
Footnotes
Support statement: This work was funded by the Health and Social Care Research and Development Division, Public Health Agency, Northern Ireland and the Medical Research Council through a US-Ireland Partnership Grant. Funding information for this article has been deposited with theCrossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article atwww.qdcxjkg.com
- ReceivedAugust 21, 2017.
- AcceptedNovember 17, 2017.
- Copyright ©ERS 2018